Canada Approves Hologic Aptima Assays for HPV | GenomeWeb

NEW YORK (GenomeWeb News) – Hologic said on Thursday that Canadian regulators approved two of the company's assays for the detection of high-risk strains of human papillomavirus.

Health Canada granted medical device licenses to Hologic's Aptima HPV and Aptima HPV 16 18/45 genotype assays. Both assays are in vitro nucleic acid amplification tests for detecting HPV strains that are associated with cervical cancer and precancerous lesions, Hologic said. The assays were approved to run on the company's Tigris instrument.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.